We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MBL International Corporation Introduces AngioPhase(TM) Angiogenesis Kit
Product News

MBL International Corporation Introduces AngioPhase(TM) Angiogenesis Kit

MBL International Corporation Introduces AngioPhase(TM) Angiogenesis Kit
Product News

MBL International Corporation Introduces AngioPhase(TM) Angiogenesis Kit


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "MBL International Corporation Introduces AngioPhase(TM) Angiogenesis Kit"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Angiogenesis is the multistep process whereby new blood vessels develop from pre-existing vasculature. It plays a key role in the natural process of healing and reproduction but also in many pathological processes including cancer, skin diseases, age-related blindness, diabetic ulcers, cardiovascular disease, and stroke.

AngioPhase(TM) incorporates a patented technology, developed by TCS Cellworks Limited, Buckingham, UK, in which human endothelial cells are co-cultured with other human cells in a specially designed medium. Under the terms of the non-exclusive agreement with TCS Cellworks Limited, MBL International Corporation has been granted a license to manufacture and sell the assay in North and South America.

"MBL International is excited about adding AngioPhase to our growing portfolio of life sciences products," said Dennis Walczewski, CEO MBL International Corporation. "This technology offers many benefits to researchers in the biotechnology and pharmaceutical industries by offering a ready-to-use angiogenesis kit in which test compounds can be added at any time. Moreover, both angiogenic simulators and inhibitors can be assessed as well as tubule formation."

"We are pleased to enter into this licensing agreement with MBL International Corporation," stated Tim Almond CEO of TCS Cellworks. "They have demonstrated not only a strong commitment to manufacturing high quality products but also an impressive business model which leverages the superior technical expertise of their commercial team."

Advertisement